FindMyKOL
Clinical trialNCT03526536TerminatedPhase 4Interventional

Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD

NCT03526536 is a phase 4 interventional trial sponsored by State University of New York - Downstate Medical Center. As of 18 Nov 2026, it was terminated. It studies IV Novolin R human insulin in Diabetes Mellitus and End-Stage Renal Disease. The registry lists an enrollment of 40 participants at 1 site in 1 country. The registry lists a start date of 1 May 2018 and a primary completion date of 3 Sept 2020.

SponsorState University of New York - Downstate Medical Center →Enrollment40Diabetes MellitusEnd-Stage Renal Disease
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03526536
FieldValue
Registry IDNCT03526536
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorState University of New York - Downstate Medical Center
Enrollment40
Registered sites1
Countries1
ConditionsDiabetes Mellitus and End-Stage Renal Disease
DrugsIV Novolin R human insulin
Start1 May 2018
Primary completion3 Sept 2020
Study completion3 Sept 2020
Last update posted26 Oct 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is for people with diabetes who have either healthy kidneys or who have end stage renal disease (ESRD) and are on hemodialysis that are having surgery. This research will help increase our knowledge about how having diseased kidneys and being on hemodialysis changes how the body responds to insulin. In the time period directly before, during, and after surgery, maintenance of blood sugar within normal physiological range is essential. When patients come for surgery and have an elevated blood sugar, it is up to each individual physician to decide on the right amount of insulin to treat them. Currently, there are many different protocols across the country to treat elevated blood sugar; however, there is no one specific protocol to treat elevated blood sugar at SUNY Downstate Medical Center at this time. In this study, the investigators will evaluate the change in blood sugar following insulin administration to determine whether there is a significantly different response between ESRD and non-ESRD patients. The results of the study will help develop safer practice guidelines to patients with ESRD with an elevated blood sugar while they are having surgery.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Ketan Shevde, MD

    State University of New York - Downstate Medical Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Suny Downstate Medical Center

    Brooklyn

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IV Novolin R human insulin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03526536

Each answer restates registry values shown on this page.

What is NCT03526536?

NCT03526536 is a phase 4 interventional trial sponsored by State University of New York - Downstate Medical Center. It studies IV Novolin R human insulin in Diabetes Mellitus and End-Stage Renal Disease.

Who leads NCT03526536?

The registry names Ketan Shevde, MD (principal investigator, State University of New York - Downstate Medical Center) as the overall official.

Where does NCT03526536 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03526536 study?

The registered drug and biological interventions are IV Novolin R human insulin.

When did NCT03526536 end?

The registry lists a primary completion date of 3 Sept 2020 and a study completion date of 3 Sept 2020. The sponsor last updated the record on 26 Oct 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.